• Facebook
  • Twitter
  • LinkedIn
  • Youtube
  • Mail
  • For Patients
  • Customer Login
  • Newsletter Sign-up
Profound Medical
  • Home
  • News
    • Events
  • Physicians
    • Customizable Incision-Free Therapies
  • Technology
    • TULSA-PRO®
    • Sonalleve®
  • Company
    • About
    • Leadership Team
    • Board of Directors
    • Careers
    • Clinical Publications
  • Investors
    • Profile
    • Governance
    • Presentations
    • TACT Data
    • Webcasts
    • Financial
    • Press Releases
    • Analyst Coverage
    • Subscribe
  • Contact
  • Menu Menu

Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA)

Agron Lumiani M.D, Diyala Samun Dip.-Ing., Ronald Sroka Ph.D., Rolf Muschter M.D.

The TULSA Procedure is offered in routine clinical practice at the ALTA Klinik (Bielefeld, Germany) to men with prostate cancer seeking minimally invasive treatment. Results from a clinical service evaluation performed at the clinic, intended to assess benefit in the real-world setting, were published in Urologic Oncology. The report included 52 men with D’ Amico low (13%), medium (67%), or high-risk (19%) prostate cancer receiving the TULSA Procedure either as initial treatment for prostate cancer, or for recurrent disease after other modalities failed (2 HIFU, 1 laser+HIFU, 1 EBRT, 1 hyperthermia).

A combination treatment was delivered in 24/52 of the men (46%) targeting both cancer and benign prostatic hyperplasia (BPH) in a single procedure.  Treatment plans were customized for patient-specific disease characteristics and to spare important anatomy. A 3 mm margin around the urinary sphincter was incorporated to reduce the risk of incontinence, and, where feasible, neurovascular bundles were spared to reduce the risk of impotence. According to the authors, the range of prostate volume at baseline was 17-122 cc and the fraction of gland targeted ranged from less than 50% to whole-gland (Figure 1). The following outcomes were assessed at median (IQR) 16 (12-22) months: early treatment success for prostate cancer, based on mpMRI, biochemical recurrence (Phoenix), and confirmatory biopsy; relief of LUTS (lower urinary tract symptoms, for men receiving combination treatment); adverse events; preservation of continence and potency.

After a single TULSA Procedure, early treatment success for prostate cancer was achieved in 38 men (73%). Of the nine men who elected for a repeat TULSA Procedure, 8 achieved early treatment success at follow up (median time=14 months) increasing the rate of early treatment success after first or second TULSA Procedure to 88%. The majority of men underwent partial ablation (80%). All men who were previously fully potent, and 44/45 (98%) of men with full or partial potency at baseline, maintained erectile function. Pad-free continence was preserved in 51/52 (98%) of men. After the combination treatment targeting the prostate cancer and BPH, improvement in LUTS was achieved for 20/24 (83%) of men. Two complications requiring intervention (without general anesthesia) were observed, and there were no bowel-related complications.

The authors note that partial ablation had better preservation of urinary continence and erectile function compared with whole-gland, and fewer adverse events. Within the subset of patients who incurred a recurrence after the first TULSA procedure, one man underwent a non-complicated radical prostatectomy. Patients with high-risk disease at baseline had higher risk of recurrence, and there was no recurrence among men with low-risk disease at baseline. The following causes for failure were identified: suboptimal screening for calcifications, and insufficient thermal margins.

Based on these results, the authors of this study found the TULSA Procedure to be safe and effective at treating low to high-risk prostate cancer in the real-world setting, and also at simultaneously relieving LUTS through customized treatment plans, both as a primary treatment or a salvage treatment delivered after other modalities fail. Repeat TULSA Procedure is feasible if needed to achieve definitive treatment.

To read more about this study, visit: https://www.sciencedirect.com/science/article/pii/S1078143921001733

Recent Posts

  • AUA Happy Hour
  • How did you hear about us
  • (no title)
  • SONALLEVE WEBINAR: March 30th 2022
  • Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA)

Categories

  • Blog Post
  • CEO Update
  • Events
  • Frontpage Article
  • News
  • Uncategorized
  • Whitepapers

Tags

CEO Message CONALLEVE Corona Corona Virus COVID-19 Erectile Dysfunction Erectile Function EUROPE FLA HIFU meeting PATIENT PROFOUND PROSTATE RELEASE SOFTWARE SONALLEVE TACT TDC tulsa TULSA-PRO TULSAPRO tulsa procedure TULSAPROCEDURE TULSA TREATMENT Webinar

News

AUA Happy Hour

April 19, 2022
Read more
https://profoundmedical.com/wp-content/uploads/2022/04/Profound-Happy-Hour-Invite_ad-scaled.jpg 1344 2560 Profound Medical https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Profound Medical2022-04-19 16:16:442022-04-20 17:19:49AUA Happy Hour

SONALLEVE WEBINAR: March 30th 2022

February 23, 2022
Read more
https://profoundmedical.com/wp-content/uploads/2022/02/2022.03.30_Sonalleve-Webinar_Web-Image-scaled.jpg 1344 2560 Profound Medical https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Profound Medical2022-02-23 11:38:422022-03-30 05:48:14SONALLEVE WEBINAR: March 30th 2022

Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA)

October 4, 2021
Read more
https://profoundmedical.com/wp-content/uploads/2021/09/ALTA-Study-Blog-Image.png 2550 3300 Profound Medical https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Profound Medical2021-10-04 00:00:582021-09-29 15:26:42Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA)

Careers & Training

  • Careers
  • Customer Login
  • TULSA-PRO Training

Head Office

Profound Medical Corp.,
2400 Skymark Avenue,
Unit #6, Mississauga, ON  L4W 5K5, Canada

T: 647.476.1350 
F:
 647.847.3739
info@profoundmedical.com

 
© Copyright - Profound Medical 2021
  • Home
  • Physicians
  • TULSA PRO
  • Patients
  • Company
  • News
  • Investors
  • Contact
  • Customer Login
  • TULSA-PRO Training
  • Privacy Policy
Why wait—A customizable, focal to whole gland intervention for prostate tissue...SONALLEVE WEBINAR: March 30th 2022
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn More

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only